Rosiglitazone reduces a wide range of proinflammatory profiles in synovial fibroblast SW982 under spheroid culture

Immunology Letters

Volumn 131, Issue 1, 2010, Pages 81-88

  Song, Jin Sook ^a   Kim, Chi Hyun ^a   Heo, Jun Young ^a   Cho, Young Sik ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Arthritis; Fibroblast like synoviocytes; Rosiglitazone; SW982

Indexed keywords

COLLAGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; ROSIGLITAZONE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; MONOLAYER CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; UPREGULATION;

ANIMALS; ANKLE JOINT; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL LINE; FIBROBLASTS; HUMANS; MALE; MICE; MICE, INBRED DBA; SPHEROIDS, CELLULAR; SYNOVIAL MEMBRANE; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 77954759655     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.02.010     Document Type: Article

References (22)

1. Abou-Raya A., Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2005, 5:331-337.
2. Kobayashi K., Suda T., Manabe H., Miki I. Administration of PDE4 inhibitors suppressed the pannus-like inflammation by inhibition of cytokine production by macrophages and synovial fibroblast proliferation. Mediators Inflamm 2007, 2007:58901-58909.
3. Peter E., Lipsky P.E. Why does rheumatoid arthritis involve the joints?. N Engl J Med 2007, 356:2419-2420.
4. Chan A., Filer A., Parsonage G., Kollnberger S., Gundle R., Buckley C.D., et al. Mediation of the proinflammatory cytokine response in rheumatoid arthritis and spondylarthritis by interactions between fibroblast-like synoviocytes and natural killer cells. Arthritis Rheum 2008, 58:707-717.
5. Cha H.S., Ahn K.S., Jeon C.H., Kim J., Koh E.M. Inhibitory effect of cyclo-oxygenase-2 inhibitor on the production of matrix metalloproteinases in rheumatoid fibroblast-like synoviocytes. Rheumatol Int 2004, 24:207-211.
6. Wada Y., Shimada K., Kimura T., Ushiyama S. Novel p38 MAP kinase inhibitor R-130823 suppresses IL-6, IL-8 and MMP-13 production in spheroid culture of human synovial sarcoma cell line SW982. Immunol Lett 2005, 101:50-59.
7. Kim K.W., Cho M.L., Lee S.H., Oh H.J., Kang C.M., Ju J.H., et al. Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANK. Immunol Lett 2007, 110:54-64.
8. Ospelt C., Kyburz D., Pierer M., Seibl R., Kurowska M., Distler O., et al. Toll-like receptors in rheumatoid arthritis joint destruction mediated by two distinct pathways. Ann Rheum Dis 2004, 63:ii90-ii91.
9. Watkins S.M., Reifsnyder P.R., Pan H.J., German J.B., Leiter E.H. Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J Lipid Res 2002, 43:1809-1817.
10. Tontonoz P., Hu E., Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor 1. Cell 1994, 79:1147-1156.
11. Nakajima A., Wada K., Miki H., Kubota N., Nakajima N., Terauchi Y., et al. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 2001, 120:460-469.
12. Cuzzocrea S., Mazzon E., Dugo L., Patel N.S., Serraino I., Di Paola R., et al. Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma. Arthritis Rheum 2003, 48:3544-3556.
13. Campbell I.K., Hamilton J.A., Wicks I.P. Collagen-induced arthritis in C57BL/6 (H-2b) mice: new insights into an important disease model of rheumatoid arthritis. Eur J Immunol 2000, 30:1568-1575.
14. Shiojiri T., Wada K., Nakajima A., Katayama K., Shibuya A., Kudo C., et al. PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. Eur J Pharmacol 2002, 448:231-238.
15. Tomita T., Kakiuchi Y., Tsao P.S. THR0921, a novel peroxisome proliferator-activated receptor gamma agonist, reduces the severity of collagen-induced arthritis. Arthritis Res Ther 2006, 8:R7.
16. Polch-Puy E., Granell S., Iovanna J.L., Barthet M., Closa D. Peroxisome-proliferator-activated receptor gamma agonist reduces the severity of post-ERCP pancreatitis in rats. World J Gastroenterol 2006, 12:6458-6463.
17. Dubuquoy L., Dharancy S., Nutten S., Pettersson S., Auwerx J., Desreumaux P. Role of peroxisome proliferator-activated receptor gamma and retinoid×receptor heterodimer in hepatogastroenterological diseases. Lancet 2002, 360:1410-1508.
18. Tsuji F., Oki K., Senda T., Horiuchi M., Mita S. Effects of mitogen-activated protein kinase inhibitors or phosphodiesterase inhibitors on interleukin-1-induced cytokines production in synovium-derived cells. Immunol Lett 1999, 68:275-279.
19. Han Z., Boyle D.L., Chang L., Bennett B., Karin M., Yang L., et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001, 108:73-81.
20. Simonin M.A., Bordji K., Boyault S., Bianchi A., Gouze E., Becuwe P. PPAR-γ ligands modulate effects of LPS in stimulated rat synovial fibroblast. Am J Physiol 2002, 282:C125-C133.
21. Moulin D., Bianchi A., Boyault S., Sebillaud S., Koufany M., Francois M., et al. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1β-stimulated rat synovial fibroblast via a peroxisome proliferator-activated receptor β/δ-dependent mechanism. Arthritis Rheum 2005, 52:759-769.
22. Weber S.M., Scarim A.L., Corbett J.A. PPARgamma is not required for the inhibitory actions of PGJ2 on cytokine signaling in pancreatic beta-cells. Am J Physiol Endocrinol Metab 2004, 286:E329-E336.